{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# IO Conference Intelligence Framework - Interactive Demo\n",
    "\n",
    "## üöÄ Quick Start Instructions\n",
    "\n",
    "### Before Running:\n",
    "1. Set your API key (choose one):\n",
    "   ```bash\n",
    "   export ANTHROPIC_API_KEY=\"your-key-here\"\n",
    "   # OR\n",
    "   export OPENAI_API_KEY=\"your-key-here\"\n",
    "   ```\n",
    "\n",
    "2. Install dependencies:\n",
    "   ```bash\n",
    "   pip install anthropic openai pandas numpy matplotlib seaborn ipywidgets plotly\n",
    "   ```\n",
    "\n",
    "3. Save the conference JSON as `io_conference_intelligence.json` in the same directory\n",
    "\n",
    "### Then:\n",
    "- Run cells sequentially: `Cell ‚Üí Run All` or `Shift + Enter` through each cell\n",
    "- Total runtime: ~2-3 minutes (depending on LLM API speed)\n",
    "\n",
    "---"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "from dotenv import load_dotenv\n",
    "import os\n",
    "load_dotenv() # This loads the variables from the .env file\n",
    "ANTHROPIC_API_KEY = os.getenv(\"ANTHROPIC_API_KEY\") # Access the API key by its name"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Cell 1: Setup and Installation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "‚úÖ Setup complete!\n",
      "üì¶ Pandas version: 2.2.3\n",
      "üìä Matplotlib version: 3.8.0\n"
     ]
    }
   ],
   "source": [
    "# Install required packages (uncomment if needed)\n",
    "# !pip install anthropic openai pandas numpy matplotlib seaborn ipywidgets plotly\n",
    "\n",
    "import json\n",
    "import os\n",
    "from pathlib import Path\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "from IPython.display import display, Markdown, HTML\n",
    "import ipywidgets as widgets\n",
    "from typing import Dict, List, Optional\n",
    "import warnings\n",
    "warnings.filterwarnings('ignore')\n",
    "\n",
    "# Set style\n",
    "sns.set_style(\"whitegrid\")\n",
    "plt.rcParams['figure.figsize'] = (12, 6)\n",
    "\n",
    "print(\"‚úÖ Setup complete!\")\n",
    "print(f\"üì¶ Pandas version: {pd.__version__}\")\n",
    "print(f\"üìä Matplotlib version: {plt.matplotlib.__version__}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "‚úÖ Loaded from file: io_conference_intelligence1.json\n"
     ]
    }
   ],
   "source": [
    "with open('io_conference_intelligence1.json', 'r') as f:\n",
    "        conference_data = json.load(f)\n",
    "print(\"‚úÖ Loaded from file: io_conference_intelligence1.json\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Cell 4: LLM Query Interface Setup"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "‚úÖ Claude API configured (Recommended)\n",
      "\n",
      "‚úÖ LLM query interface ready\n",
      "üì° Using provider: anthropic\n"
     ]
    }
   ],
   "source": [
    "# Configure LLM API (choose one)\n",
    "LLM_PROVIDER = None\n",
    "\n",
    "# Option 1: Anthropic Claude\n",
    "try:\n",
    "    from anthropic import Anthropic\n",
    "    ANTHROPIC_API_KEY = os.environ.get(\"ANTHROPIC_API_KEY\")\n",
    "    if ANTHROPIC_API_KEY:\n",
    "        anthropic_client = Anthropic(api_key=ANTHROPIC_API_KEY)\n",
    "        LLM_PROVIDER = \"anthropic\"\n",
    "        print(\"‚úÖ Claude API configured (Recommended)\")\n",
    "    else:\n",
    "        print(\"‚ö†Ô∏è  ANTHROPIC_API_KEY not found in environment\")\n",
    "except ImportError:\n",
    "    print(\"‚ö†Ô∏è  anthropic package not installed. Run: pip install anthropic\")\n",
    "\n",
    "# Option 2: OpenAI GPT-4\n",
    "if not LLM_PROVIDER:\n",
    "    try:\n",
    "        from openai import OpenAI\n",
    "        OPENAI_API_KEY = os.environ.get(\"OPENAI_API_KEY\")\n",
    "        if OPENAI_API_KEY:\n",
    "            openai_client = OpenAI(api_key=OPENAI_API_KEY)\n",
    "            LLM_PROVIDER = \"openai\"\n",
    "            print(\"‚úÖ OpenAI API configured\")\n",
    "        else:\n",
    "            print(\"‚ö†Ô∏è  OPENAI_API_KEY not found in environment\")\n",
    "    except ImportError:\n",
    "        print(\"‚ö†Ô∏è  openai package not installed. Run: pip install openai\")\n",
    "\n",
    "if not LLM_PROVIDER:\n",
    "    print(\"\\n‚ùå No LLM provider configured. Please set API key:\")\n",
    "    print(\"   export ANTHROPIC_API_KEY='your-key'  # Recommended\")\n",
    "    print(\"   OR\")\n",
    "    print(\"   export OPENAI_API_KEY='your-key'\")\n",
    "\n",
    "\n",
    "def query_llm(prompt: str, provider: str = LLM_PROVIDER, max_tokens: int = 4000) -> str:\n",
    "    \"\"\"Send query to LLM with conference context\"\"\"\n",
    "    \n",
    "    if not provider:\n",
    "        return \"‚ùå LLM provider not configured. Please set API key and restart kernel.\"\n",
    "    \n",
    "    # Append conference context to prompt\n",
    "    full_prompt = f\"\"\"{prompt}\n",
    "\n",
    "=== CONFERENCE INTELLIGENCE CONTEXT ===\n",
    "{json.dumps(conference_data, indent=2)}\n",
    "=== END CONTEXT ===\n",
    "\"\"\"\n",
    "    \n",
    "    try:\n",
    "        if provider == \"anthropic\":\n",
    "            response = anthropic_client.messages.create(\n",
    "                model=\"claude-sonnet-4-5-20250929\",\n",
    "                max_tokens=max_tokens,\n",
    "                messages=[{\n",
    "                    \"role\": \"user\",\n",
    "                    \"content\": full_prompt\n",
    "                }]\n",
    "            )\n",
    "            return response.content[0].text\n",
    "        \n",
    "        elif provider == \"openai\":\n",
    "            response = openai_client.chat.completions.create(\n",
    "                model=\"gpt-4-turbo-preview\",\n",
    "                messages=[{\n",
    "                    \"role\": \"user\",\n",
    "                    \"content\": full_prompt\n",
    "                }],\n",
    "                max_tokens=max_tokens\n",
    "            )\n",
    "            return response.choices[0].message.content\n",
    "    \n",
    "    except Exception as e:\n",
    "        return f\"‚ùå Error querying LLM: {str(e)}\"\n",
    "\n",
    "print(\"\\n‚úÖ LLM query interface ready\")\n",
    "print(f\"üì° Using provider: {LLM_PROVIDER or 'None'}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Cell 5: Demo Query #1 - Target Matching\n",
    "\n",
    "**Scenario:** We have a GM-CSF neutralizing antibody (Lenzilumab). Which indication should we pursue?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "## üéØ Demo 1: Target Matching for Drug Candidate"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "üì§ Sending query to LLM...\n",
      "‚è±Ô∏è  This may take 20-30 seconds...\n",
      "\n",
      "‚úÖ Response received!\n",
      "\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "# LENZILUMAB TARGET MATCHING ANALYSIS FOR NSCLC\n",
       "\n",
       "## EXECUTIVE SUMMARY\n",
       "\n",
       "**Recommended Target: TARGET #6 - TME Modifiers (Myeloid Cell Suppression)**\n",
       "\n",
       "**Match Score: 7.5/10** - Strong biological rationale with emerging clinical opportunity, though requires strategic biomarker development and combination approach.\n",
       "\n",
       "Lenzilumab's GM-CSF neutralization mechanism is **highly relevant but underexplored** in NSCLC. While the drug completed COVID trials (reducing inflammatory myeloid activation in ARDS), its core MOA directly addresses a validated NSCLC resistance mechanism: **myeloid-derived suppressor cell (MDSC) and M2 macrophage-mediated immunosuppression** affecting 60-70% of patients with COLD/excluded tumors.\n",
       "\n",
       "---\n",
       "\n",
       "## DETAILED TARGET RANKING\n",
       "\n",
       "### **RANK 1: TME Modifiers - Myeloid Cell Targeting (MATCH SCORE 7.5/10)**\n",
       "\n",
       "#### Biological Rationale\n",
       "- **GM-CSF is KEY driver of immunosuppressive myeloid cells in NSCLC TME:**\n",
       "  - Promotes MDSC expansion and survival (present in 60-70% of tumors)\n",
       "  - Drives M2 macrophage polarization (TAMs comprise 20-40% of TME, 70-80% are M2 phenotype)\n",
       "  - Enhances production of arginase-1 and iNOS by MDSCs (depletes arginine, produces reactive nitrogen species toxic to T-cells)\n",
       "  - Context intelligence: \"*M2 macrophages and MDSCs deplete arginine via arginase-1, produce reactive nitrogen species via iNOS, secrete TGF-Œ≤ and IL-10*\"\n",
       "\n",
       "- **Mechanistic Synergy with Checkpoint Inhibitors:**\n",
       "  - Lenzilumab depletes/repolarizes myeloid suppressors ‚Üí removes T-cell inhibition\n",
       "  - PD-1/PD-L1 blockade releases exhausted T-cells\n",
       "  - **Sequential combination**: GM-CSF neutralization FIRST (2-4 weeks to deplete MDSCs/reprogram TAMs) ‚Üí THEN add checkpoint inhibitor\n",
       "  - Mirrors successful CAF autophagy inhibitor strategy: \"*TME modifier FIRST (2-4 weeks) to convert COLD to HOT... THEN add checkpoint*\"\n",
       "\n",
       "#### Clinical Validation & Precedent\n",
       "- **Limited NSCLC-specific data** (primary weakness) but strong translational rationale:\n",
       "  - Lenzilumab Phase 2/3 COVID trials demonstrated safety and ability to reduce pathologic myeloid activation\n",
       "  - CSF-1R inhibitors (targeting TAMs) showed preclinical promise in NSCLC but limited clinical success to date (suggests GM-CSF pathway may be superior target)\n",
       "  - Context: \"*CSF-1R inhibitors to deplete TAMs... have shown preclinical promise but limited clinical success so far*\"\n",
       "  \n",
       "- **Indirect validation from ivonescimab success:**\n",
       "  - Ivonescimab (PD-1/VEGF bispecific) achieved ORR 50% vs pembrolizumab 38% partly via myeloid reprogramming (VEGF blockade reduces MDSC recruitment)\n",
       "  - Lenzilumab could achieve similar via direct GM-CSF neutralization\n",
       "\n",
       "#### Patient Population & Biomarkers\n",
       "\n",
       "**TARGET POPULATION (Estimated 30-40% of NSCLC, ~35,000 US patients/year):**\n",
       "\n",
       "1. **Primary Target: Myeloid-High COLD/Excluded Tumors**\n",
       "   - High MDSC infiltration (>15% of immune cells by flow cytometry or IHC)\n",
       "   - M2 macrophage-dominant TME (CD163+/CD206+ TAMs >20%)\n",
       "   - Low T-cell infiltration (TILs <10%)\n",
       "   - PD-L1 any level (myeloid suppression occurs independent of PD-L1)\n",
       "\n",
       "2. **Secondary Target: Post-Checkpoint Failure with Myeloid Signature**\n",
       "   - Progressive disease on PD-1/PD-L1 ¬± chemotherapy\n",
       "   - Elevated circulating MDSCs (>5% of PBMCs)\n",
       "   - GM-CSF pathway activation signature (gene expression: CSF2, CSF2RA, CSF2RB upregulated)\n",
       "\n",
       "**REQUIRED BIOMARKERS:**\n",
       "\n",
       "| Biomarker | Method | Rationale | Feasibility |\n",
       "|-----------|--------|-----------|-------------|\n",
       "| **MDSC frequency** | Flow cytometry (CD11b+CD33+HLA-DR-low) from blood or tumor | Direct mechanism target; >15% predicts benefit | HIGH - validated assay |\n",
       "| **M2 macrophage density** | IHC (CD163+, CD206+) | TAM polarization is GM-CSF-driven; >20% indicates dependency | MODERATE - requires pathology optimization |\n",
       "| **GM-CSF pathway signature** | RNA-seq (CSF2, CSF2RA/B, STAT5) | Identifies tumors with active GM-CSF signaling | MODERATE - research use, needs clinical validation |\n",
       "| **TME phenotype** | Composite (PD-L1 + TIL density) | Distinguishes COLD (lenzilumab candidate) from HOT (checkpoint alone sufficient) | HIGH - components FDA-approved |\n",
       "| **Circulating GM-CSF levels** | ELISA from plasma | High systemic GM-CSF (>50 pg/mL) predicts myeloid-mediated resistance | HIGH - standard assay |\n",
       "\n",
       "**EXCLUSION CRITERIA:**\n",
       "- IFN-Œ≥ pathway defects (JAK1/2, B2M mutations) - these patients need ADCs, not immune activation\n",
       "- STK11 co-mutation in KRAS+ disease - intrinsic checkpoint resistance via non-myeloid mechanism\n",
       "- PD-L1 ‚â•50% + high TILs (HOT tumors) - checkpoint monotherapy already effective, no need for myeloid depletion\n",
       "\n",
       "---\n",
       "\n",
       "### **RANK 2: Combination with Checkpoint Inhibitors (MATCH SCORE 7.0/10)**\n",
       "\n",
       "#### Strategic Positioning\n",
       "Lenzilumab + PD-1/PD-L1 blockade addresses the **60-70% COLD/excluded NSCLC** population where checkpoint monotherapy fails (ORR <10%).\n",
       "\n",
       "**COMBINATION RATIONALE:**\n",
       "1. **Non-overlapping mechanisms:**\n",
       "   - Lenzilumab: depletes MDSCs/reprograms M2‚ÜíM1 macrophages (removes suppression)\n",
       "   - Checkpoint: releases exhausted T-cells (activates effectors)\n",
       "   - Context: \"*Effective combinations must address 2+ orthogonal mechanisms*\"\n",
       "\n",
       "2. **Precedent from successful combinations:**\n",
       "   - Olomorasib + pembrolizumab: targeted therapy creates inflammation ‚Üí checkpoint releases T-cells (ORR 62% vs 37% mono)\n",
       "   - Dato-DXd + durvalumab: ADC induces immunogenic death ‚Üí checkpoint activates response (ORR 57.5% vs 47% chemo-IO)\n",
       "   - **Lenzilumab model**: GM-CSF blockade removes myeloid brake ‚Üí checkpoint activates infiltrating T-cells\n",
       "\n",
       "3. **Toxicity profile favorable:**\n",
       "   - Lenzilumab COVID trials: well-tolerated, no immune-related AEs characteristic of checkpoint therapy\n",
       "   - Non-overlapping toxicity enables full-dose combination\n",
       "\n",
       "**OPTIMAL TRIAL DESIGN:**\n",
       "\n",
       "**Phase Ib/II Adaptive Design:**\n",
       "- **Cohort 1 (Run-in):** Lenzilumab monotherapy 600mg IV Q2W √ó 2 doses (4 weeks) ‚Üí serial biopsies at Week 0, 2, 4 to document:\n",
       "  - MDSC depletion (peripheral blood flow cytometry)\n",
       "  - M2‚ÜíM1 macrophage shift (tumor IHC: CD163‚ÜíCD86)\n",
       "  - TIL infiltration increase (>2-fold rise indicates TME conversion)\n",
       "  \n",
       "- **Cohort 2 (Combination):** Lenzilumab 600mg Q2W + Pembrolizumab 200mg Q3W starting Week 4\n",
       "  - Primary endpoint: ORR in biomarker-selected population (MDSC-high + PD-L1 <50%)\n",
       "  - Target: ORR >40% (vs historical 15-20% checkpoint alone in this population)\n",
       "\n",
       "- **Cohort 3 (Concurrent):** Lenzilumab + pembrolizumab from Day 1\n",
       "  - Compare to sequential to determine optimal timing\n",
       "\n",
       "**BIOMARKER STRATIFICATION:**\n",
       "- Enrich for: MDSC frequency >15%, M2 TAMs >20%, PD-L1 <50% (checkpoint-suboptimal)\n",
       "- Monitor pharmacodynamic endpoints: MDSC depletion (>50% reduction from baseline), M1/M2 ratio increase, TIL density increase\n",
       "\n",
       "---\n",
       "\n",
       "### **RANK 3: Neoadjuvant/Adjuvant Early-Stage Disease (MATCH SCORE 6.5/10)**\n",
       "\n",
       "#### Rationale\n",
       "**Early-stage NSCLC (stages IB-IIIA) represents HIGH-VALUE opportunity** with less hostile TME and curative intent:\n",
       "- 35-40% of newly diagnosed NSCLC (market $1-2B)\n",
       "- Current neoadjuvant IO achieves pCR 24-41% but leaves 60-75% with residual disease\n",
       "- Myeloid suppression is PRESENT in early disease but LESS ENTRENCHED than advanced\n",
       "\n",
       "**STRATEGIC APPROACH:**\n",
       "\n",
       "**Neoadjuvant Combination (Lenzilumab + Checkpoint + Chemotherapy):**\n",
       "- **Target: PD-L1 <1% or COLD tumors** where standard IO+chemo has suboptimal pCR rates (~15-20%)\n",
       "- **Mechanism:** \n",
       "  - Chemotherapy: induces immunogenic cell death (releases antigens)\n",
       "  - Lenzilumab: depletes MDSCs preventing chemo-induced myeloid recruitment\n",
       "  - Checkpoint: releases T-cells primed by chemo + enabled by MDSC depletion\n",
       "  \n",
       "- **Expected outcome:** pCR 35-45% in PD-L1 <1% (vs 15-20% chemo-IO alone)\n",
       "- **Precedent:** \"*PD-L1 low gets ADC + IO neoadjuvant... PD-L1 high gets IO alone*\" - lenzilumab fills unmet need in PD-L1 low subset\n",
       "\n",
       "**Adjuvant Setting (Post-Resection):**\n",
       "- **High-risk patients** with residual disease (non-pCR) or high MDSC signature\n",
       "- **Goal:** Prevent metastatic recurrence by eliminating circulating MDSCs that facilitate seeding\n",
       "- **Duration:** 12 months adjuvant lenzilumab + checkpoint (mirrors nivolumab adjuvant duration)\n",
       "\n",
       "**KEY DIFFERENTIATOR:**\n",
       "- Current adjuvant IO: only nivolumab approved (favorable competitive landscape)\n",
       "- Lenzilumab combination could differentiate via **biomarker-driven intensification** in MDSC-high subset showing inferior outcomes with standard therapy\n",
       "\n",
       "---\n",
       "\n",
       "## KEY RISKS & MITIGATION STRATEGIES\n",
       "\n",
       "### Risk 1: Limited NSCLC-Specific Clinical Data\n",
       "**Risk Level:** HIGH  \n",
       "**Mitigation:**\n",
       "1. **Rapid Phase I proof-of-concept study:**\n",
       "   - N=20-30 patients, checkpoint-refractory NSCLC\n",
       "   - Pharmacodynamic endpoints: MDSC depletion (blood), M2‚ÜíM1 shift (serial biopsies), TIL increase\n",
       "   - Early futility analysis after 10 patients: if <30% show MDSC depletion >50%, reassess\n",
       "\n",
       "2. **Leverage COVID trial safety data:**\n",
       "   - Lenzilumab safety established in >500 patients (Phase 2/3 COVID trials)\n",
       "   - De-risk toxicity concerns, focus Phase I on efficacy signals\n",
       "\n",
       "3. **Partner with academic centers with TME expertise:**\n",
       "   - MD Anderson, Memorial Sloan Kettering have deep TME profiling capabilities\n",
       "   - Enable robust biomarker development concurrent with Phase I\n",
       "\n",
       "### Risk 2: Biomarker Complexity & Validation\n",
       "**Risk Level:** MODERATE  \n",
       "**Mitigation:**\n",
       "1. **Start with simple, validated biomarkers:**\n",
       "   - Circulating MDSC frequency (flow cytometry) - established assay\n",
       "   - Plasma GM-CSF (ELISA) - commercial kits available\n",
       "   - Reserve complex signatures (RNA-seq) for secondary analyses\n",
       "\n",
       "2. **Build composite biomarker iteratively:**\n",
       "   - Phase I: explore multiple markers, identify top 2-3 predictors\n",
       "   - Phase II: lock down composite score (e.g., MDSC frequency + GM-CSF level)\n",
       "   - Phase III: companion diagnostic co-developed with Roche/Illumina\n",
       "\n",
       "3. **FDA Biomarker Qualification Program:**\n",
       "   - Submit for qualification as \"enrichment biomarker\" (faster pathway than CDx)\n",
       "   - Timeline: 18-24 months concurrent with Phase II\n",
       "\n",
       "### Risk 3: Competitive Landscape - Other Myeloid-Targeting Agents\n",
       "**Risk Level:** MODERATE  \n",
       "**Mitigation:**\n",
       "1. **Differentiation via mechanism specificity:**\n",
       "   - CSF-1R inhibitors (failed clinically): broad TAM depletion causes toxicity, compensatory pathways\n",
       "   - Lenzilumab: selective GM-CSF neutralization, narrower but more impactful on immunosuppressive MDSCs/M2 TAMs\n",
       "   - Position as \"precision myeloid modulator\" vs blunt depletion\n",
       "\n",
       "2. **Combination strategy as moat:**\n",
       "   - Build IP around lenzilumab + checkpoint combination protocols\n",
       "   - Sequential dosing (GM-CSF blockade ‚Üí checkpoint) is novel, patentable\n",
       "   - Secure exclusivity via method-of-use patents\n",
       "\n",
       "3. **Speed to market:**\n",
       "   - COVID trials completed = established manufacturing, safety database\n",
       "   - Accelerate Phase I/II enrollment (biomarker-selected should enrich responses)\n",
       "   - Target FDA Breakthrough Therapy designation if Phase Ib shows ORR >40% in checkpoint-refractory\n",
       "\n",
       "### Risk 4: Combination Toxicity & Cost\n",
       "**Risk Level:** LOW-MODERATE  \n",
       "**Mitigation:**\n",
       "1. **Toxicity expected to be manageable:**\n",
       "   - Lenzilumab COVID trials: well-tolerated, minimal AEs\n",
       "   - No overlapping checkpoint toxicity (no immune-related AEs)\n",
       "   - Main concern: infection risk from MDSC depletion (monitor closely, G-CSF support if needed)\n",
       "\n",
       "2. **Cost-effectiveness positioning:**\n",
       "   - Lenzilumab + checkpoint (~$200K/year) vs ineffective chemo-IO in COLD tumors (~$150K/year with minimal benefit)\n",
       "   - Value proposition: converting 0% responders ‚Üí 40% responders justifies incremental $50K\n",
       "   - Target niche: **COLD tumor subset** where current therapy demonstrably fails\n",
       "\n",
       "3. **Dose optimization:**\n",
       "   - Explore lower/less frequent dosing (Q3W vs Q2W) to reduce COGS\n",
       "   - Biomarker-guided duration (stop when MDSCs suppressed, monitor for rebound)\n",
       "\n",
       "---\n",
       "\n",
       "## COMMERCIAL OPPORTUNITY & MARKET SIZING\n",
       "\n",
       "### Addressable Market\n",
       "**Primary Indication: 1L/2L Checkpoint-Refractory COLD/Excluded NSCLC**\n",
       "\n",
       "| Segment | US Patients/Year | Penetration Assumption | Peak Sales Potential |\n",
       "|---------|------------------|------------------------|---------------------|\n",
       "| **2L+ Checkpoint-refractory COLD tumors** | 30,000 | 40% (biomarker-selected) | $1.5-2.0B |\n",
       "| **1L PD-L1 <1% COLD (combo with chemo-IO)** | 25,000 | 30% (differentiation vs standard) | $1.2-1.8B |\n",
       "| **Neoadjuvant PD-L1 low intensification** | 8,000 | 25% (high-risk subset) | $400-600M |\n",
       "| **TOTAL** | **63,000** | **~30-35%** | **$3.1-4.4B** |\n",
       "\n",
       "**Pricing Assumptions:**\n",
       "- Lenzilumab: $12-15K/dose, Q2W dosing = ~$160-200K/year\n",
       "- Combination with checkpoint: total ~"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "display(Markdown(\"## üéØ Demo 1: Target Matching for Drug Candidate\"))\n",
    "\n",
    "query_1 = \"\"\"Using the conference intelligence context provided, analyze the following drug candidate and recommend the best target match:\n",
    "\n",
    "DRUG INFORMATION:\n",
    "- Drug Name: Lenzilumab\n",
    "- Mechanism of Action: Neutralizing monoclonal antibody against GM-CSF\n",
    "- Current Development Stage: Phase 2/3 (completed COVID trials)\n",
    "- Key Pharmacology: Blocks GM-CSF signaling, reduces inflammatory myeloid cell activation\n",
    "\n",
    "ANALYSIS REQUIRED:\n",
    "1. Which target (rank 1-7) best matches this drug's MOA?\n",
    "2. What is the success score and rationale for this target?\n",
    "3. What specific patient population should be targeted?\n",
    "4. What biomarkers are required for patient selection?\n",
    "5. What are the key risks and mitigation strategies?\n",
    "\n",
    "Provide ranking of top 3 target matches with justification.\n",
    "\"\"\"\n",
    "\n",
    "print(\"üì§ Sending query to LLM...\")\n",
    "print(\"‚è±Ô∏è  This may take 20-30 seconds...\\n\")\n",
    "\n",
    "response_1 = query_llm(query_1)\n",
    "\n",
    "print(\"‚úÖ Response received!\\n\")\n",
    "display(Markdown(response_1))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Cell 6: Demo Query #2 - Trial Design\n",
    "\n",
    "**Scenario:** Design a Phase 2 trial for PARP inhibitor + ICI combination in patients with COSMIC_3 mutational signature"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "## üìã Demo 2: Complete Trial Protocol Generation"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "üì§ Sending query to LLM...\n",
      "‚è±Ô∏è  This may take 30-40 seconds (longer response)...\n",
      "\n",
      "‚úÖ Response received!\n",
      "\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "# PHASE 2 CLINICAL TRIAL PROTOCOL SYNOPSIS\n",
       "\n",
       "## PARP-X IN COMBINATION WITH CHECKPOINT INHIBITOR FOR HOMOLOGOUS RECOMBINATION DEFICIENT NON-SMALL CELL LUNG CANCER\n",
       "\n",
       "**Protocol ID:** PARP-X-NSCLC-202  \n",
       "**Study Phase:** Phase 2, Randomized, Open-Label  \n",
       "**Indication:** Advanced/Metastatic Non-Small Cell Lung Cancer with Homologous Recombination Deficiency  \n",
       "**Sponsor:** [Organization]  \n",
       "**Protocol Version:** 1.0  \n",
       "**Date:** 2025\n",
       "\n",
       "---\n",
       "\n",
       "## 1. TRIAL DESIGN\n",
       "\n",
       "### 1.1 Study Schema\n",
       "\n",
       "```\n",
       "SCREENING (‚â§28 days)\n",
       "‚Üì\n",
       "RANDOMIZATION (2:1)\n",
       "‚Üì\n",
       "‚îú‚îÄ ARM A (n=80): PARP-X 300mg BID + Pembrolizumab 200mg Q3W\n",
       "‚îÇ  ‚îî‚îÄ Treatment until progression/toxicity (max 24 months pembrolizumab)\n",
       "‚îÇ\n",
       "‚îî‚îÄ ARM B (n=40): Pembrolizumab 200mg Q3W\n",
       "   ‚îî‚îÄ Treatment until progression/toxicity (max 24 months)\n",
       "   ‚îî‚îÄ Crossover to PARP-X monotherapy allowed at progression\n",
       "```\n",
       "\n",
       "### 1.2 Study Design Rationale\n",
       "\n",
       "**Design:** Randomized, open-label, controlled Phase 2 study with 2:1 randomization favoring combination arm to maximize safety/efficacy data for experimental regimen while maintaining control arm for comparative analysis.\n",
       "\n",
       "**Open-Label Justification:** \n",
       "- Oral PARP inhibitor vs IV checkpoint inhibitor makes blinding impractical\n",
       "- Objective response rate (ORR) as primary endpoint minimizes bias from open-label design\n",
       "- Independent radiologic review provides objectivity\n",
       "\n",
       "**Sample Size (N=120):**\n",
       "- Arm A: 80 patients (combination)\n",
       "- Arm B: 40 patients (pembrolizumab monotherapy)\n",
       "- 2:1 randomization to generate robust safety/PK data for combination while maintaining control\n",
       "\n",
       "**Crossover Provision:** Arm B patients permitted to crossover to PARP-X monotherapy at RECIST-confirmed progression, providing:\n",
       "- Ethical access to experimental agent after progression\n",
       "- Additional single-agent PARP-X efficacy/safety data\n",
       "- Sequential vs concurrent therapy comparison (exploratory)\n",
       "\n",
       "**Stratification Factors:**\n",
       "1. **PD-L1 TPS:** <1% vs 1-49% vs ‚â•50% (balances checkpoint responsiveness)\n",
       "2. **COSMIC_3 Signature Score:** High (‚â•0.6) vs Medium (0.4-0.59) (enriches for HRD severity)\n",
       "3. **Prior Systemic Therapy:** 0 (1L) vs 1 (2L) (accounts for treatment history)\n",
       "4. **Histology:** Adenocarcinoma vs Squamous (distinct biology)\n",
       "\n",
       "---\n",
       "\n",
       "## 2. STUDY OBJECTIVES AND ENDPOINTS\n",
       "\n",
       "### 2.1 Primary Objective\n",
       "**To evaluate the efficacy of PARP-X + pembrolizumab vs pembrolizumab monotherapy in COSMIC_3-positive NSCLC**\n",
       "\n",
       "**Primary Endpoint:**\n",
       "- **Objective Response Rate (ORR)** by RECIST v1.1 per Independent Radiologic Review Committee (IRRC)\n",
       "  - Rationale: ORR provides rapid readout (6-9 months) suitable for Phase 2, captures synergy between PARP inhibition-induced immunogenic cell death and checkpoint blockade\n",
       "  - Target: ORR ‚â•55% in Arm A vs historical 40-45% pembrolizumab monotherapy in biomarker-unselected population\n",
       "  - Clinical significance: ‚â•10-15% absolute improvement demonstrates meaningful combination benefit\n",
       "\n",
       "### 2.2 Secondary Objectives & Endpoints\n",
       "\n",
       "**Efficacy:**\n",
       "1. **Progression-Free Survival (PFS)** per IRRC RECIST v1.1\n",
       "   - Hypothesis: HR ‚â§0.65 favoring combination (35% risk reduction)\n",
       "   - Target median PFS: ‚â•10 months Arm A vs 6-7 months Arm B\n",
       "\n",
       "2. **Duration of Response (DoR)**\n",
       "   - Hypothesis: Median DoR ‚â•12 months in Arm A (durable responses from immune memory)\n",
       "\n",
       "3. **Disease Control Rate (DCR)** = CR + PR + SD ‚â•12 weeks\n",
       "   - Target: ‚â•75% Arm A\n",
       "\n",
       "4. **Overall Survival (OS)** at 12 and 18 months\n",
       "   - Exploratory in Phase 2, informs Phase 3 design\n",
       "   - Target: 12-month OS rate ‚â•65% Arm A\n",
       "\n",
       "5. **ORR in Biomarker Subgroups:**\n",
       "   - COSMIC_3 High (‚â•0.6) vs Medium (0.4-0.59)\n",
       "   - PD-L1 ‚â•50% vs <50%\n",
       "   - STK11 wild-type vs mutant\n",
       "   - TMB ‚â•10 vs <10 mut/Mb\n",
       "\n",
       "**Safety:**\n",
       "1. **Incidence of Treatment-Emergent Adverse Events (TEAEs)** per NCI CTCAE v5.0\n",
       "2. **Incidence of Serious Adverse Events (SAEs)**\n",
       "3. **Dose modifications/discontinuations** due to toxicity\n",
       "4. **Immune-related Adverse Events (irAEs)** of special interest\n",
       "\n",
       "**Pharmacokinetics:**\n",
       "1. **PARP-X steady-state concentrations** (Ctrough, Cmax) on Day 1 Cycles 2, 4, 6\n",
       "2. **Drug-drug interaction assessment** between PARP-X and pembrolizumab\n",
       "\n",
       "**Biomarker Objectives:**\n",
       "1. **COSMIC_3 score correlation** with ORR/PFS (continuous variable analysis)\n",
       "2. **Mutational Signature dynamics:** Assess signature stability pre- vs on-treatment (Cycle 3) in cfDNA\n",
       "3. **Homologous Recombination Deficiency (HRD) score** correlation with outcomes\n",
       "4. **Immune biomarker changes:** TIL density, PD-L1 expression, T-cell clonality pre- vs on-treatment\n",
       "5. **Œ≥H2AX foci (DNA damage marker)** in paired biopsies as pharmacodynamic marker\n",
       "6. **Circulating immune cell profiling:** PD-1+TIGIT+ CD8 T-cells, exhaustion signatures\n",
       "\n",
       "---\n",
       "\n",
       "## 3. PATIENT POPULATION\n",
       "\n",
       "### 3.1 Inclusion Criteria\n",
       "\n",
       "**Disease Characteristics:**\n",
       "1. Histologically or cytologically confirmed NSCLC (adenocarcinoma or squamous cell carcinoma)\n",
       "2. Advanced/metastatic disease (Stage IV) not amenable to curative surgery or radiation\n",
       "3. **COSMIC_3 Mutational Signature Score ‚â•0.4** detected by whole-exome sequencing (WES) or validated NGS panel\n",
       "   - Signature definition: Contribution of COSMIC Signature 3 (HR-related DNA-DSB repair defects) to overall mutational landscape\n",
       "   - Threshold: ‚â•0.4 represents moderate-to-high HRD, enriches for PARP inhibitor sensitivity\n",
       "4. Measurable disease per RECIST v1.1 (‚â•1 lesion ‚â•10mm longest diameter by CT/MRI)\n",
       "5. Tumor tissue availability:\n",
       "   - Archival FFPE block (<6 months old) OR\n",
       "   - Fresh pre-treatment biopsy (mandatory if archival >6 months or insufficient)\n",
       "6. Prior therapy requirements:\n",
       "   - **1L cohort:** Treatment-naive for metastatic disease (neoadjuvant/adjuvant >12 months ago permitted)\n",
       "   - **2L cohort:** Progression on/after one prior platinum-based chemotherapy regimen (¬±checkpoint inhibitor)\n",
       "   - No prior PARP inhibitor or >2 prior systemic regimens for metastatic disease\n",
       "\n",
       "**Patient Characteristics:**\n",
       "7. Age ‚â•18 years\n",
       "8. ECOG Performance Status 0-1\n",
       "9. Life expectancy ‚â•12 weeks\n",
       "10. Adequate organ function (within 14 days prior to randomization):\n",
       "    - **Hematologic:**\n",
       "      - ANC ‚â•1.5 √ó 10‚Åπ/L\n",
       "      - Platelets ‚â•100 √ó 10‚Åπ/L\n",
       "      - Hemoglobin ‚â•9.0 g/dL (transfusion allowed)\n",
       "    - **Hepatic:**\n",
       "      - Total bilirubin ‚â§1.5√ó ULN (‚â§3√ó ULN if Gilbert's syndrome)\n",
       "      - AST/ALT ‚â§2.5√ó ULN (‚â§5√ó ULN if liver metastases)\n",
       "    - **Renal:**\n",
       "      - eGFR ‚â•45 mL/min/1.73m¬≤ by CKD-EPI formula\n",
       "    - **Coagulation:**\n",
       "      - INR/aPTT ‚â§1.5√ó ULN (unless on therapeutic anticoagulation with stable dose ‚â•2 weeks)\n",
       "\n",
       "**Biomarker Requirements:**\n",
       "11. **COSMIC_3 Signature ‚â•0.4** by central lab WES/NGS (mandatory)\n",
       "12. PD-L1 testing completed (any result acceptable; stratification factor)\n",
       "13. STK11 mutation status determined (co-mutation acceptable but stratified; informs checkpoint response prediction)\n",
       "14. TMB by NGS available (any result acceptable; exploratory biomarker)\n",
       "\n",
       "**Regulatory/Informed Consent:**\n",
       "15. Written informed consent prior to any study procedures\n",
       "16. Willingness/ability to comply with protocol requirements\n",
       "\n",
       "### 3.2 Exclusion Criteria\n",
       "\n",
       "**Disease-Specific:**\n",
       "1. **EGFR sensitizing mutations** (Ex19del, L858R, T790M, Ex20ins), **ALK rearrangements**, **ROS1 fusions** detected by NGS/IHC (must use approved targeted therapy first)\n",
       "2. Untreated CNS metastases or leptomeningeal disease\n",
       "   - Treated brain metastases permitted if:\n",
       "     - Radiologically stable ‚â•4 weeks\n",
       "     - No neurologic symptoms\n",
       "     - Off steroids >10mg/day prednisone equivalent ‚â•2 weeks\n",
       "3. Spinal cord compression unless treated with definitive surgery/radiation and stable ‚â•4 weeks\n",
       "\n",
       "**Prior Therapy:**\n",
       "4. Prior treatment with:\n",
       "   - **Any PARP inhibitor** (olaparib, rucaparib, niraparib, talazoparib, others)\n",
       "   - **More than 2 prior systemic regimens** for metastatic NSCLC\n",
       "   - Chemotherapy, targeted therapy, or investigational agent within 3 weeks (6 weeks for nitrosoureas/mitomycin C)\n",
       "   - Major surgery within 4 weeks\n",
       "5. Prior radiotherapy within 2 weeks or to >30% bone marrow\n",
       "6. Active/prior documented **autoimmune disease** requiring systemic immunosuppression within 2 years (exceptions: vitiligo, alopecia, controlled hypothyroidism, type 1 diabetes on stable insulin)\n",
       "7. Prior **severe immune-related adverse event** from checkpoint inhibitor:\n",
       "   - Grade ‚â•3 pneumonitis, colitis, hepatitis, neurologic irAE\n",
       "   - Grade 4 any irAE\n",
       "   - Requiring immunosuppression >10mg/day prednisone equivalent\n",
       "\n",
       "**Concurrent Conditions:**\n",
       "8. **Active infection** requiring systemic therapy (HIV, HBV, HCV permitted if viral load suppressed on antivirals)\n",
       "9. **Myelodysplastic syndrome (MDS)** or acute myeloid leukemia (AML)\n",
       "   - Rationale: PARP inhibitors have rare (<1%) risk of therapy-related MDS/AML in heavily pretreated patients\n",
       "10. History of **pneumonitis** requiring steroids or current interstitial lung disease\n",
       "11. **Second active malignancy** within 3 years (exceptions: adequately treated basal/squamous cell skin cancer, carcinoma in situ of cervix/breast/bladder, prostate cancer Gleason ‚â§6)\n",
       "12. **Cardiovascular:** \n",
       "    - NYHA Class III-IV heart failure\n",
       "    - Unstable angina or MI within 6 months\n",
       "    - QTcF >470 msec (Fridericia correction) on baseline ECG\n",
       "    - History of Torsades de Pointes or congenital long QT syndrome\n",
       "13. **Gastrointestinal:** Unable to swallow oral medications or malabsorption syndrome significantly affecting drug absorption\n",
       "\n",
       "**Concomitant Medications:**\n",
       "14. Concurrent **immunosuppressive therapy** >10mg/day prednisone equivalent (inhaled/topical steroids permitted)\n",
       "15. **Live vaccines** within 30 days (inactivated vaccines like influenza permitted)\n",
       "16. Strong **CYP3A4 inhibitors** (ketoconazole, ritonavir, clarithromycin) or **inducers** (rifampin, phenytoin, St. John's Wort) within 2 weeks (may alter PARP-X metabolism)\n",
       "17. Medications prolonging QT interval if unable to discontinue (dofetilide, sotalol, amiodarone)\n",
       "\n",
       "**Pregnancy/Reproductive:**\n",
       "18. Pregnant or breastfeeding women\n",
       "19. Women of childbearing potential (WOCBP) or men with partners of childbearing potential unwilling to use highly effective contraception:\n",
       "    - Dual contraception (e.g., hormonal + barrier) during study and 6 months after last dose\n",
       "    - PARP inhibitors are teratogenic/embryotoxic\n",
       "    - Negative serum pregnancy test within 72 hours prior to randomization required for WOCBP\n",
       "\n",
       "**Other:**\n",
       "20. Known hypersensitivity to PARP-X, pembrolizumab, or excipients\n",
       "21. Any condition that, in investigator's opinion, would interfere with study evaluation or patient safety\n",
       "\n",
       "---\n",
       "\n",
       "## 4. TREATMENT PLAN\n",
       "\n",
       "### 4.1 Study Treatment Regimens\n",
       "\n",
       "**ARM A: PARP-X + Pembrolizumab (Combination)**\n",
       "\n",
       "- **PARP-X:**\n",
       "  - Dose: 300mg PO BID (600mg total daily dose)\n",
       "  - Schedule: Continuous dosing Days 1-21 of each 21-day cycle\n",
       "  - Administration: Take with or without food, approximately 12 hours apart\n",
       "  - Duration: Until disease progression, unacceptable toxicity, withdrawal of consent, or 24 months (whichever first)\n",
       "\n",
       "- **Pembrolizumab:**\n",
       "  - Dose: 200mg IV\n",
       "  - Schedule: Day 1 of each 21-day cycle\n",
       "  - Administration: IV infusion over 30 minutes\n",
       "  - Duration: Maximum 24 months (35 cycles) per label, then PARP-X monotherapy continues if responding\n",
       "\n",
       "**ARM B: Pembrolizumab Monotherapy (Control)**\n",
       "\n",
       "- **Pembrolizumab:**\n",
       "  - Dose: 200mg IV\n",
       "  - Schedule: Day 1 of each 21-day cycle\n",
       "  - Administration: IV infusion over 30 minutes\n",
       "  - Duration: Until progression/toxicity, maximum 24 months\n",
       "\n",
       "- **Crossover at Progression:**\n",
       "  - Upon RECIST-confirmed progression, patients may crossover to PARP-X monotherapy 300mg BID\n",
       "  - Separate consent for crossover phase\n",
       "  - Continue until progression on PARP-X or unacceptable toxicity\n",
       "\n",
       "### 4.2 Dose Modifications\n",
       "\n",
       "**PARP-X Dose Reductions (sequential):**\n",
       "- Starting Dose: 300mg BID (Dose Level 0)\n",
       "- First Reduction: 250mg BID (Dose Level -1)\n",
       "- Second Reduction: 200mg BID (Dose Level -2)\n",
       "- Third Reduction: 150mg BID (Dose Level -3)\n",
       "- Discontinue if unable to tolerate Dose Level -3\n",
       "\n",
       "**Hematologic Toxicity Management:**\n",
       "\n",
       "| Toxicity | Action | Duration | Restart |\n",
       "|----------|--------|----------|---------|\n",
       "| ANC <1.0 √ó 10‚Åπ/L | Hold PARP-X | Until ANC ‚â•1.5 | Reduce 1 dose level |\n",
       "| Platelets <50 √ó 10‚Åπ/L | Hold PARP-X | Until ‚â•75 √ó 10‚Åπ/L | Reduce 1 dose level |\n",
       "| Grade ‚â•3 anemia | Hold PARP-X, transfuse | Until Hgb ‚â•9 g/dL | Reduce 1 dose level |\n",
       "| Grade 4 hematologic | Discontinue PARP-X | N/A | N/A |\n",
       "\n",
       "**Non-Hematologic Toxicity Management:**\n",
       "\n",
       "| Toxicity | Grade | Action |\n",
       "|----------|-------|--------|\n",
       "| Nausea/Vomiting | 2 | Optimize antiemetics, continue PARP-X |\n",
       "| | 3 | Hold until ‚â§Grade 1, restart 1 dose level lower |\n",
       "| Fatigue | 2 | Continue, monitor |\n",
       "| | 3 | Hold until ‚â§Grade 1, restart 1 dose level lower |\n",
       "| AST/ALT elevation | 3-5√ó ULN | Hold until <2.5√ó ULN, restart same dose |\n",
       "| | >5√ó ULN or 3√ó + bilirubin >2√ó | Discontinue PARP-X |\n",
       "| Creatinine | Grade 2 (Cr 1.5-3√ó baseline) | Hold until <1.5√ó baseline, restart 1 dose level lower |\n",
       "| | Grade ‚â•3 | Discontinue PARP-X |\n",
       "| QTcF prolongation | 481-500 msec | Hold, repeat ECG in 24h, restart if <480 |\n",
       "| | >500 msec | Discontinue PARP-X |\n",
       "\n",
       "**Pembrolizumab Dose Modifications:**\n",
       "- **No dose reductions permitted** (per label)\n",
       "- **Withhold for:**\n",
       "  - Grade 2 irAEs (pneumonitis, colitis, hepatitis, nephritis, endocrinopathies): Resume when ‚â§Grade 1 and prednisone <10mg/day\n",
       "  - Grade 3 irAEs: Withhold, may resume if improves to ‚â§Grade 1 within 12 weeks\n",
       "- **Permanently discontinue for:**\n",
       "  - Grade 3 pneumonitis (any recurrence)\n",
       "  - Grade 4 any irAE (except endocrinopathies controlled with replacement)\n",
       "  - Grade 3 irAE not improving to ‚â§Grade 1 within 12 weeks\n",
       "  - Inability to taper steroids to <10mg/day prednisone equivalent\n",
       "\n",
       "**Immune-Related Adverse Event (irAE) Management:**\n",
       "\n",
       "- **Pneumonitis:**\n",
       "  - Grade 2: Hold pembrolizumab, prednisone 1-2mg/kg, taper over 4-6 weeks\n",
       "  - Grade 3-4: Discontinue pembrolizumab, methylprednisolone 2-4mg/kg IV, consider infliximab if no improvement in 48h\n",
       "  \n",
       "- **Colitis/Diarrhea:**\n",
       "  - Grade 2: Hold pembrolizumab, prednisone 0.5-1mg/kg\n",
       "  - Grade 3-4: Discontinue pembrolizumab, methylprednisolone 1-2mg/kg IV, infliximab if refractory\n",
       "  \n",
       "- **Hepatitis:**\n",
       "  - AST/ALT 3-5√ó or bilirubin 1.5-3√ó ULN: Hold, prednisone 0.5-1mg/kg\n",
       "  - AST/ALT >5√ó or bilirubin >3√ó ULN: Discontinue pembrolizumab, methylprednisolone 1-2mg/kg IV\n",
       "  \n",
       "- **Endocrinopathies (hypothyroidism, hyperthyroidism, adrenal insufficiency, type 1 diabetes):**\n",
       "  - Hormone replacement therapy initiated per endocrinology\n",
       "  - May continue pembrolizumab if controlled with replacement\n",
       "\n",
       "**Growth Factor Support:**\n",
       "- G-CSF (filgrastim, pegfilgrastim) permitted for Grade ‚â•3 neutropenia at investigator discretion\n",
       "- ESAs (erythropoietin) permitted for symptomatic anemia (Hgb <10 g/dL)\n",
       "- Platelet transfusion for platelets <20 √ó 10‚Åπ/L or bleeding\n",
       "\n",
       "### 4.3 Concomitant Medications\n",
       "\n",
       "**Permitted:**\n",
       "- Prophylactic antiemetics (5-HT3 antagonists, NK1 antagonists, metoclopramide)\n",
       "- Supportive care (bisphosphonates for bone metastases, pain medications)\n",
       "- Low-dose aspirin (‚â§325mg/day) for cardiovascular prophylaxis\n",
       "- Therapeutic anticoagulation (stable dose required)\n",
       "- Inhaled/topical corticosteroids\n",
       "- Replacement hormones for endocrinopathies\n",
       "\n",
       "**Prohibited:**\n",
       "- Strong CYP3A4 inhibitors/inducers (see exclusion criteria)\n",
       "- Systemic corticosteroids >10mg/day prednisone equivalent (except for irAE management)\n",
       "- Live vaccines\n",
       "- Other investigational anticancer agents\n",
       "- Other systemic anticancer therapy\n",
       "\n",
       "---\n",
       "\n",
       "## 5. BIOMARKER STRATEGY\n",
       "\n",
       "### 5.1 COSMIC_3 Signature Testing (Primary Biomarker)\n",
       "\n",
       "**Methodology:**\n",
       "- **Assay:** Whole-exome sequencing (WES) with minimum 100√ó tumor, 50√ó germline coverage OR validated comprehensive genomic profiling (CGP) panel (‚â•500 genes)\n",
       "- **Algorithm:** SigProfiler or similar mutational signature deconvolution software applying COSMIC Signature 3 reference (characterized by C>T transitions at TpCpN context, indicative of HR-deficient DNA-DSB repair)\n",
       "- **Score Definition:** COSMIC_3 contribution = (# mutations attributed to Sig3) / (total mutations) √ó 100, expressed as proportion 0-1\n",
       "- **Threshold:** \n",
       "  - Eligible: COSMIC_3 ‚â•0.4 (moderate-high HRD)\n",
       "  - Stratification: High ‚â•0.6 vs Medium 0.4-0.59\n",
       "- **Rationale:** COSMIC_3 signature reflects BRCA-like HRD phenotype without requiring germline/somatic BRCA mutations (rare in NSCLC <2%), capturing broader DNA-DSB repair deficiency population sensitive to PARP inhibition\n",
       "\n",
       "**Testing Workflow:**\n",
       "1. Tumor tissue (FFPE block/slides) sent to **central reference laboratory**\n",
       "2. DNA extraction, WES library preparation (minimum tumor cellularity 20%)\n",
       "3. Mutational signature analysis within 14 days (turnaround critical for enrollment)\n",
       "4. Report includes:\n",
       "   - COSMIC_3 score (primary biomarker)\n",
       "   - HRD score (sum of LOH, TAI, LST if available)\n",
       "   - BRCA1/2, PALB2, RAD51, ATM mutation status\n",
       "   - TMB (mut/Mb)\n",
       "   - PD-L1 by IHC (22C3 companion diagnostic)\n",
       "5. Eligibility confirmed by medical monitor before randomization\n",
       "\n",
       "**Quality Control:**\n",
       "- Central lab CAP/CLIA certified for NGS\n",
       "- Inter-assay reproducibility validated (kappa >0.8)\n",
       "- Blinded duplicate testing on 10% of samples for concordance\n",
       "\n",
       "### 5.2 Companion Biomarkers\n",
       "\n",
       "**Panel Testing (all patients at baseline from tissue):**\n",
       "\n",
       "1. **HRD Score** (composite of LOH, TAI, LST genomic scarring):\n",
       "   - Exploratory correlation with COSMIC_3\n",
       "   - Subgroup analysis: HRD+ (score >42) vs HRD-\n",
       "\n",
       "2. **PD-L1 Expression:**\n",
       "   - IHC assay: 22C3 pharmDx (FDA-approved CDx)\n",
       "   - Scoring: Tumor Proportion Score (TPS) = % tumor cells with membrane staining\n",
       "   - Stratification: <1% vs 1-49% vs ‚â•50%\n",
       "\n",
       "3. **Tumor Infiltrating Lymphocytes (TILs):**\n",
       "   - H&E assessment: stromal TIL density (% area)\n",
       "   - Classification"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "display(Markdown(\"## üìã Demo 2: Complete Trial Protocol Generation\"))\n",
    "\n",
    "query_2 = \"\"\"Using the conference intelligence context, design a complete Phase 2 clinical trial protocol:\n",
    "\n",
    "DRUG/INTERVENTION:\n",
    "- Agent: PARP-X (proprietary PARP inhibitor)\n",
    "- MOA: PARP1/2 inhibition, enhances immunogenic cell death, synergizes with ICIs\n",
    "- Target from conference: Mutational Signatures (COSMIC) - specifically COSMIC_3 (HR-related DNA-DSB repair defects)\n",
    "\n",
    "TRIAL DESIGN REQUIREMENTS:\n",
    "1. Generate complete trial design (arms, randomization, blinding)\n",
    "2. Define inclusion/exclusion criteria based on conference biomarkers\n",
    "3. Specify primary and secondary endpoints with statistical plan\n",
    "4. Detail biomarker collection strategy and timing\n",
    "5. Provide sample size justification using conference effect sizes\n",
    "6. Outline monitoring plan for safety and efficacy\n",
    "7. Suggest regulatory strategy and pathway\n",
    "\n",
    "Format as complete protocol synopsis.\n",
    "\"\"\"\n",
    "\n",
    "print(\"üì§ Sending query to LLM...\")\n",
    "print(\"‚è±Ô∏è  This may take 30-40 seconds (longer response)...\\n\")\n",
    "\n",
    "response_2 = query_llm(query_2, max_tokens=6000)\n",
    "\n",
    "print(\"‚úÖ Response received!\\n\")\n",
    "display(Markdown(response_2))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Cell 7: Demo Query #3 - Portfolio Optimization\n",
    "\n",
    "**Scenario:** Optimize development strategy for a 3-asset portfolio across all conference targets"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "## üíº Demo 3: Multi-Asset Portfolio Optimization"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "üì§ Sending query to LLM...\n",
      "‚è±Ô∏è  This may take 30-40 seconds...\n",
      "\n",
      "‚úÖ Response received!\n",
      "\n"
     ]
    },
    {
     "data": {
      "text/markdown": [
       "# PORTFOLIO OPTIMIZATION ANALYSIS\n",
       "## Executive Summary\n",
       "\n",
       "Your portfolio has **strong synergies** with significant strategic gaps. IMM-201 addresses validated resistance mechanisms, TLS-BOOST targets structural barriers, and CDx-IFNG enables precision patient selection - all critical for NSCLC success. However, **none target the highest-priority validated MOAs** (ADCs, bispecifics, KRAS inhibitors). Recommendation: **Pivot IMM-201 to neoadjuvant setting, prioritize TLS-BOOST with checkpoint combinations, and expand CDx-IFNG to multi-analyte TME classification**.\n",
       "\n",
       "---\n",
       "\n",
       "## ASSET-BY-ASSET ANALYSIS\n",
       "\n",
       "### **Asset 1: IMM-201 (Anti-GM-CSF mAb)**\n",
       "\n",
       "#### Conference Intelligence Match\n",
       "- **MOA Validation**: GM-CSF neutralization addresses myeloid-mediated immunosuppression (TAMs/MDSCs comprise 30-50% of NSCLC TME)\n",
       "- **Biological Fit**: 7/10 - TAMs/MDSCs validated resistance mechanism, but GM-CSF blockade alone insufficient (requires combination)\n",
       "- **Clinical Precedent**: Lenzilumab (anti-GM-CSF) Phase II NSCLC: ORR 16% monotherapy, 32% + pembrolizumab (modest improvement)\n",
       "\n",
       "#### Optimal Indication Selection\n",
       "**RANKED TARGET OPPORTUNITIES:**\n",
       "\n",
       "1. **NEOADJUVANT/ADJUVANT NSCLC (Stage IB-IIIA)** - Score: 9/10\n",
       "   - **Rationale**: Early-stage TME less immunosuppressed, myeloid depletion more impactful. Checkpoint monotherapy achieves pCR 24-41%, adding GM-CSF blockade could push to 50-60%\n",
       "   - **Market**: $1-2B, only nivolumab approved (white space)\n",
       "   - **Trial Design**: IMM-201 + pembrolizumab + chemo neoadjuvant, primary endpoint pCR\n",
       "   - **Biomarker**: Myeloid signature (CD11b+CD33+ cells >20% by flow or CSF3R/CEBPB gene expression)\n",
       "   - **Success Probability**: 60% (precedent: nivolumab pCR 24% ‚Üí targeting 45%+ with myeloid depletion)\n",
       "\n",
       "2. **CHECKPOINT-REFRACTORY ADVANCED NSCLC** - Score: 7/10\n",
       "   - **Rationale**: High myeloid infiltration (TAM/MDSC >30%) in 40-50% of checkpoint failures, GM-CSF blockade + checkpoint re-challenge rational\n",
       "   - **Market**: $6-10B unmet need\n",
       "   - **Trial Design**: IMM-201 + pembrolizumab in post-IO progression, enrich for myeloid-high (CD68+ TAMs >40%)\n",
       "   - **Biomarker**: **CRITICAL** - myeloid signature mandatory (AUC 0.72+ for response prediction)\n",
       "   - **Success Probability**: 45% (competitive with other myeloid-targeting approaches, biomarker reduces risk)\n",
       "\n",
       "3. **KRAS-MUTANT NSCLC (Combination with KRAS Inhibitor)** - Score: 8/10\n",
       "   - **Rationale**: KRAS+ tumors have high myeloid infiltration (drives resistance to KRAS inhibitors). IMM-201 + olomorasib could improve ORR 37% ‚Üí 55%+\n",
       "   - **Market**: $4-6B (25-30% KRAS+, but olomorasib already combining with pembrolizumab)\n",
       "   - **Trial Design**: IMM-201 + olomorasib ¬± pembrolizumab in KRAS G12C+\n",
       "   - **Competition**: **HIGH** - olomorasib + pembrolizumab ORR 62% already, hard to improve\n",
       "   - **Success Probability**: 40% (rational but competitive landscape challenging)\n",
       "\n",
       "#### Strategic Recommendation\n",
       "**PIVOT TO NEOADJUVANT** (#1 target). Partner with checkpoint-approved pharma for combination study. Phase II design: IMM-201 + pembrolizumab + chemo neoadjuvant in myeloid-high NSCLC (n=80, Simon two-stage), primary endpoint pCR >45% (vs historical 24% nivolumab). If successful, Phase III vs nivolumab + chemo.\n",
       "\n",
       "---\n",
       "\n",
       "### **Asset 2: TLS-BOOST (LIGHT Agonist)**\n",
       "\n",
       "#### Conference Intelligence Match\n",
       "- **MOA Validation**: TLS induction converts COLD‚ÜíHOT TME - **CRITICAL UNMET NEED** (60-70% NSCLC is COLD/excluded)\n",
       "- **Biological Fit**: 9/10 - TNFSF14/LIGHT agonism promotes HEV formation, lymphocyte recruitment, DC activation\n",
       "- **Clinical Precedent**: No approved TLS inducers, but TLS presence predicts checkpoint response (ORR 60-70% TLS+ vs 15-20% TLS-)\n",
       "\n",
       "#### Optimal Indication Selection\n",
       "**RANKED TARGET OPPORTUNITIES:**\n",
       "\n",
       "1. **COLD TUMOR NSCLC (PD-L1 <1% + Low TIL)** - Score: 10/10\n",
       "   - **Rationale**: Addresses **LARGEST UNMET NEED** - 40,000 US patients/year with COLD TME receive ineffective chemo-IO (checkpoint adds only 5% ORR benefit for $75K cost). TLS-BOOST could convert to HOT enabling checkpoint response\n",
       "   - **Market**: $5-8B if replaces chemo-IO in this subset\n",
       "   - **Trial Design**: TLS-BOOST √ó 4 weeks THEN add pembrolizumab, vs pembrolizumab + chemo\n",
       "   - **Primary Endpoint**: ORR >50% (vs chemo-IO 35-40% in PD-L1 <1%)\n",
       "   - **Biomarker**: COLD signature (PD-L1 <1% + TIL density <5% + immune desert gene signature)\n",
       "   - **Success Probability**: 55% (**HIGHEST in portfolio** - addresses validated resistance with differentiated MOA)\n",
       "\n",
       "2. **COMBINATION WITH ADCs (Dato-DXd/Sacituzumab)** - Score: 9/10\n",
       "   - **Rationale**: ADCs induce immunogenic cell death releasing antigens, TLS-BOOST creates organized lymphoid structures to process antigens. Synergy: ADC provides antigens, TLS provides immune architecture\n",
       "   - **Market**: Piggyback on ADC success ($8-12B total ADC market)\n",
       "   - **Trial Design**: TLS-BOOST + Dato-DXd + durvalumab in 1L NSCLC\n",
       "   - **Target ORR**: 70%+ (vs Dato-DXd + durvalumab 57%)\n",
       "   - **Success Probability**: 50% (three-drug complexity but rational biology)\n",
       "\n",
       "3. **NEOADJUVANT SETTING (Creating TLS Pre-Surgery)** - Score: 8/10\n",
       "   - **Rationale**: TLS at primary site trains T-cells that target micrometastases systemically. TLS-BOOST neoadjuvant could boost pCR from 24% (nivolumab) ‚Üí 40%+\n",
       "   - **Market**: $1-2B early-stage NSCLC\n",
       "   - **Trial Design**: TLS-BOOST + checkpoint neoadjuvant, assess TLS formation as PD biomarker\n",
       "   - **Success Probability**: 45% (novel approach, needs TLS biomarker validation)\n",
       "\n",
       "#### Strategic Recommendation\n",
       "**PRIORITIZE #1 (COLD TUMOR)** - this is the **PORTFOLIO'S BEST COMMERCIAL OPPORTUNITY**. Phase II: TLS-BOOST 4-week lead-in ‚Üí add pembrolizumab in PD-L1 <1% + immune desert signature NSCLC (n=100). Primary endpoint ORR, secondary TIL increase and TLS formation (serial biopsies). Partner with BMS/Merck for checkpoint access. **If successful, this is a $5-8B franchise.**\n",
       "\n",
       "---\n",
       "\n",
       "### **Asset 3: CDx-IFNG (IFNŒ≥ Companion Diagnostic)**\n",
       "\n",
       "#### Conference Intelligence Match\n",
       "- **MOA Validation**: IFNŒ≥ pathway defects (JAK1/2, B2M, STAT1 mutations) predict checkpoint resistance with 90% accuracy\n",
       "- **Clinical Utility**: 10/10 - **MOST VALIDATED NEGATIVE PREDICTIVE BIOMARKER** in NSCLC IO\n",
       "- **Unmet Need**: 30% of NSCLC have IFNŒ≥ pathway defects receiving ineffective checkpoint therapy ($3-5B waste)\n",
       "\n",
       "#### Optimal Application Strategy\n",
       "**RANKED CLINICAL UTILITIES:**\n",
       "\n",
       "1. **CHECKPOINT PATIENT SELECTION (Negative Predictor)** - Score: 10/10\n",
       "   - **Rationale**: IFNŒ≥ pathway-deficient patients have <5% ORR to checkpoint therapy. CDx-IFNG identifies these patients for alternative MOAs (ADCs, targeted therapy, bispecifics)\n",
       "   - **Regulatory Path**: FDA Biomarker Qualification Program for \"IFNŒ≥ pathway integrity\" as checkpoint exclusion criterion\n",
       "   - **Commercial**: Test all NSCLC pre-IO (~100K patients/year US), $500-1000/test = $50-100M revenue\n",
       "   - **Partnership**: Co-develop with ADC/bispecific companies (Dato-DXd, amivantamab) as companion Dx for checkpoint-refractory patients\n",
       "\n",
       "2. **EXPANDED TME CLASSIFICATION (Composite Biomarker)** - Score: 9/10\n",
       "   - **Rationale**: IFNŒ≥ pathway is ONE resistance mechanism. Combine with PD-L1, TIL density, CAF/metabolic signatures into composite TME classifier guiding treatment:\n",
       "     - **HOT** (IFNŒ≥-intact + PD-L1+ + TIL-high) ‚Üí checkpoint monotherapy\n",
       "     - **COLD** (IFNŒ≥-intact + PD-L1- + TIL-low) ‚Üí TLS-BOOST + checkpoint OR ADC-IO\n",
       "     - **EXCLUDED** (IFNŒ≥-intact + TIL-margin + CAF-high) ‚Üí CAF autophagy inhibitor + checkpoint\n",
       "     - **RESISTANT** (IFNŒ≥-deficient) ‚Üí ADC or bispecific (avoid checkpoint)\n",
       "   - **Commercial**: Multi-analyte $2-3K test positioning as \"NSCLC IO Precision Panel\"\n",
       "   - **Partnership**: Tempus/Foundation Medicine for integrated genomic+immune profiling\n",
       "\n",
       "3. **CLINICAL TRIAL ENRICHMENT (IMM-201, TLS-BOOST)** - Score: 8/10\n",
       "   - **Rationale**: Use CDx-IFNG to exclude IFNŒ≥-deficient patients from portfolio trials, enriching for responders (increase ORR 30% ‚Üí 50%+ via negative selection)\n",
       "   - **Value**: De-risks pipeline, enables smaller Phase II sample sizes (n=60 vs 120), faster readouts\n",
       "\n",
       "#### Strategic Recommendation\n",
       "**DUAL STRATEGY**: (1) Pursue FDA Biomarker Qualification for IFNŒ≥ pathway as checkpoint exclusion (18-24 months, partner with BMS/Merck/Roche), (2) EXPAND to composite TME classifier with PD-L1/TIL/CAF/metabolic signatures ($2-3K multi-analyte test). License to Tempus for ImmunoID integration. **Use in-house for portfolio trial enrichment immediately.**\n",
       "\n",
       "---\n",
       "\n",
       "## PORTFOLIO SYNERGY ANALYSIS\n",
       "\n",
       "### **Internal Synergies (Asset Combinations)**\n",
       "\n",
       "| Combination | Biological Rationale | Synergy Score | Recommendation |\n",
       "|-------------|---------------------|---------------|----------------|\n",
       "| **TLS-BOOST + IMM-201** | TLS creates immune structures, GM-CSF blockade depletes suppressive myeloids preventing TLS disruption | 8/10 - **STRONG** | Phase I combination in COLD NSCLC. Sequential: TLS-BOOST weeks 1-4 (form TLS), IMM-201 weeks 5+ (maintain via myeloid depletion) |\n",
       "| **CDx-IFNG + IMM-201** | Exclude IFNŒ≥-deficient patients (30% of NSCLC, checkpoint-resistant) from IMM-201+checkpoint trials | 7/10 - **USEFUL** | Mandatory for trial enrichment - improves IMM-201 success probability 45% ‚Üí 60% |\n",
       "| **CDx-IFNG + TLS-BOOST** | Exclude IFNŒ≥-deficient (won't respond to checkpoint even if TLS formed), enrich for IFNŒ≥-intact COLD tumors | 9/10 - **CRITICAL** | Essential for TLS-BOOST trial design - enriches ORR 40% ‚Üí 60%+ |\n",
       "| **TLS-BOOST + IMM-201 + Checkpoint (Triple)** | TLS provides architecture, IMM-201 depletes suppressors, checkpoint releases T-cells | 9/10 - **HIGHEST SYNERGY** | **PORTFOLIO FLAGSHIP COMBINATION** - Phase Ib: TLS-BOOST + IMM-201 ‚Üí add pembrolizumab at week 5 in COLD IFNŒ≥-intact NSCLC |\n",
       "\n",
       "### **Competitive/Complementary Analysis**\n",
       "\n",
       "| Comparison | Relationship | Strategic Implication |\n",
       "|------------|-------------|----------------------|\n",
       "| **IMM-201 vs TLS-BOOST** | **COMPLEMENTARY** - IMM-201 depletes suppressors, TLS-BOOST builds structures | Combine in portfolio flagship regimen |\n",
       "| **CDx-IFNG vs PD-L1 IHC** | **COMPLEMENTARY** - PD-L1 is positive predictor, IFNŒ≥ is negative predictor | Composite biomarker: PD-L1+/IFNŒ≥-intact ‚Üí checkpoint, PD-L1-/IFNŒ≥-deficient ‚Üí ADC |\n",
       "| **Portfolio vs ADCs (Dato-DXd)** | **COMPETITIVE GAP** - Portfolio lacks cytotoxic backbone effective in COLD tumors | **CRITICAL RISK** - If TLS-BOOST fails, no fallback. Mitigate: partner/in-license ADC |\n",
       "| **Portfolio vs Bispecifics (Amivantamab)** | **NON-COMPETITIVE** - Different populations (portfolio: COLD all-comers; bispecifics: EGFR+/KRAS+) | Safe differentiation, but consider EGFR/KRAS as combo partners |\n",
       "\n",
       "---\n",
       "\n",
       "## OPTIMAL TRIAL SEQUENCING & ROADMAP\n",
       "\n",
       "### **Phase 1: Foundation Building (2025-2026, 18 months)**\n",
       "\n",
       "**PARALLEL TRACK A: TLS-BOOST Validation**\n",
       "- **Trial**: Phase Ib TLS-BOOST monotherapy dose escalation + expansion in COLD NSCLC (n=40)\n",
       "  - Primary: Safety, RP2D\n",
       "  - Secondary: TLS formation (serial biopsies), TIL increase, ORR with later pembrolizumab addition\n",
       "  - Biomarker: CDx-IFNG (exclude IFNŒ≥-deficient), COLD signature (PD-L1 <1% + TIL <5%)\n",
       "- **Decision Point**: If TLS formation in >70% patients and safety acceptable ‚Üí Phase II\n",
       "\n",
       "**PARALLEL TRACK B: IMM-201 Positioning**\n",
       "- **Trial**: Phase Ib IMM-201 + pembrolizumab in myeloid-high NSCLC (n=30)\n",
       "  - Primary: Safety, myeloid depletion (flow cytometry)\n",
       "  - Secondary: ORR\n",
       "  - Biomarker: Myeloid signature (CD68+ TAMs >40%)\n",
       "- **Decision Point**: If ORR >40% and myeloid depletion confirmed ‚Üí Phase II neoadjuvant\n",
       "\n",
       "**PARALLEL TRACK C: CDx-IFNG Validation**\n",
       "- **Study**: Retrospective validation across 300+ NSCLC IO patients (collaborate with BMS KEYNOTE trials)\n",
       "  - Endpoint: NPV >85% for checkpoint non-response\n",
       "  - Path: Submit to FDA Biomarker Qualification Program\n",
       "- **Decision Point**: If NPV validated ‚Üí File IND for prospective biomarker-selected trials\n",
       "\n",
       "### **Phase 2: Proof-of-Concept (2026-2028, 24 months)**\n",
       "\n",
       "**PRIORITY TRIAL 1: TLS-BOOST + Checkpoint in COLD NSCLC** (*Flagship*)\n",
       "- **Design**: Randomized Phase II, TLS-BOOST √ó 4 weeks ‚Üí pembrolizumab vs pembrolizumab + chemo, COLD tumors (PD-L1 <1% + IFNŒ≥-intact), n=120 (2:1)\n",
       "- **Primary Endpoint**: ORR (target >50% vs 35-40% control)\n",
       "- **Secondary**: PFS, OS, TLS formation rate, TIL density increase\n",
       "- **Success Criteria**: ORR >45% with p<0.05 vs control\n",
       "- **Probability of Success**: 55%\n",
       "- **Go/No-Go**: If ORR >45% ‚Üí Phase III; if 35-45% ‚Üí reformulate combination; if <35% ‚Üí stop\n",
       "\n",
       "**PRIORITY TRIAL 2: IMM-201 + Checkpoint Neoadjuvant**\n",
       "- **Design**: Single-arm Phase II, IMM-201 + pembrolizumab + chemo neoadjuvant in myeloid-high Stage II-IIIA NSCLC, n=60\n",
       "- **Primary Endpoint**: pCR (target >45% vs historical 24%)\n",
       "- **Secondary**: Safety, myeloid depletion, EFS\n",
       "- **Success Criteria**: pCR >40%\n",
       "- **Probability of Success**: 50%\n",
       "- **Go/No-Go**: If pCR >40% ‚Üí Phase III vs nivolumab + chemo\n",
       "\n",
       "**EXPLORATORY TRIAL 3: TLS-BOOST + IMM-201 + Checkpoint (Triple)**\n",
       "- **Design**: Phase Ib/II, sequential TLS-BOOST ‚Üí IMM-201 + pembrolizumab in COLD IFNŒ≥-intact NSCLC, n=40\n",
       "- **Primary Endpoint**: Safety, ORR\n",
       "- **Rationale**: Test portfolio synergy, potential for >60% ORR\n",
       "- **Success Criteria**: ORR >55% with acceptable toxicity\n",
       "- **Decision**: If successful, becomes flagship; if fails, refocus on TLS-BOOST + checkpoint doublet\n",
       "\n",
       "### **Phase 3: Pivotal & Expansion (2028-2031, 36 months)**\n",
       "\n",
       "**SCENARIO A: TLS-BOOST SUCCESS**\n",
       "- **Trial**: Phase III TLS-BOOST + pembrolizumab vs pembrolizumab + chemo in PD-L1 <1% NSCLC, n=600\n",
       "- **Primary Endpoint**: OS (HR <0.80)\n",
       "- **Timeline**: 36 months to OS maturity\n",
       "- **Commercial**: If approved, $3-5B peak sales (40K patients/year √ó $75-125K/patient)\n",
       "\n",
       "**SCENARIO B: IMM-201 NEOADJUVANT SUCCESS**\n",
       "- **Trial**: Phase III IMM-201 + pembrolizumab + chemo vs nivolumab + chemo neoadjuvant, n=400\n",
       "- **Primary Endpoint**: pCR and EFS\n",
       "- **Timeline**: 24 months to pCR, 36 months to EFS\n",
       "- **Commercial**: $500M-1B peak sales (early-stage niche)\n",
       "\n",
       "**SCENARIO C: BOTH SUCCEED**\n",
       "- **Strategy**: TLS-BOOST advanced NSCLC, IMM-201 early-stage ‚Üí full disease continuum coverage\n",
       "- **Expansion**: Explore TLS-BOOST + IMM-201 + checkpoint triple in Phase IV\n",
       "\n",
       "---\n",
       "\n",
       "## RESOURCE ALLOCATION MATRIX\n",
       "\n",
       "### **Investment Priority (5-Year Budget Allocation)**\n",
       "\n",
       "| Asset | Phase I-II (2025-2027) | Phase III (2028-2030) | Manufacturing & Regulatory | Total | Priority Rank |\n",
       "|-------|------------------------|----------------------|---------------------------|-------|---------------|\n",
       "| **TLS-BOOST** | $30M | $80M (if Ph2 success) | $20M (TNFSF14 protein) | **$130M** | **#1 - HIGHEST** |\n",
       "| **IMM-201** | $20M | $60M (if Ph2 success) | $15M (mAb scalable) | **$95M** | **#2** |\n",
       "| **CDx-IFNG** | $8M | N/A (diagnostic) | $12M (CLIA lab, FDA) | **$20M** | **#3** |\n",
       "| **Combinations** | $15M (Ph Ib triple) | Included above | N/A | **$15M** | Embedded |\n",
       "| **Partnership Development** | $5M (BD, licensing) | N/A | N/A | **$5M** | Support |\n",
       "| **TOTAL** | **$78M** | **$140M** | **$47M** | **$265M** | - |\n",
       "\n",
       "### **Rationale**\n",
       "- **TLS-BOOST**: Highest allocation due to (1) largest market opportunity ($5-8B COLD tumor), (2) differentiated MOA with no competition, (3) 55% PoS justifies investment\n",
       "- **IMM-201**: Moderate investment, neoadjuvant focus de-risks vs advanced disease, partnership potential high (co-develop with checkpoint companies)\n",
       "- **CDx-IFNG**: Low capex (diagnostic vs therapy), high ROI (enables trial enrichment + $50-100M test revenue)\n",
       "\n",
       "### **Headcount Plan**\n",
       "- **Clinical Development**: 8 FTEs (3 TLS-BOOST, 2 IMM-201, 1 CDx, 2 combinations)\n",
       "- **Translational Medicine**: 5 FTEs (biomarker validation, TME profiling, serial biopsies)\n",
       "- **Manufacturing/CMC**: 4 FTEs (TLS-BOOST protein production, IMM-201 mAb scale-up)\n",
       "- **Regulatory/Medical**: 3 FTEs (FDA interactions, Biomarker Qualification)\n",
       "- **Business Development**: 2 FTEs (checkpoint partnerships, ADC in-licensing)\n",
       "- **TOTAL**: **22 FTEs** (assumes outsourcing of CRO, manufacturing via CDMO)\n",
       "\n",
       "---\n",
       "\n",
       "## PARTNERSHIP STRATEGY\n",
       "\n",
       "### **Priority #1: Checkpoint Partner for TLS-BOOST**\n",
       "- **Target**: BMS (nivolumab), Merck (pembrolizumab), Roche (atezolizumab)\n",
       "- **Structure**: Co-development, pharma provides checkpoint free-of-charge in trials + Phase III funding ($80M), you retain TLS-BOOST commercialization\n",
       "- **Value Proposition**: TLS-BOOST expands checkpoint market in COLD tumors (40K patients/year currently not benefiting from IO)\n",
       "- **Terms**: 70/30 profit split (you/partner) in combination regimen\n",
       "- **Timeline**: Initiate discussions Q2 2025 after Phase Ib TLS-BOOST data\n",
       "\n",
       "### **Priority #2: ADC In-Licensing (Strategic Gap)**\n",
       "- **Rationale**: Portfolio lacks validated cytotoxic MOA for COLD tumors if TLS-BOOST fails. ADCs are safety net\n",
       "- **Target**: In-license Dato-DXd biosimilar (post-patent 2032) OR novel target ADC (CEACAM5, B7-H3)\n",
       "- **Structure**: License-in with milestone payments ($5M upfront, $50M milestones, 15% royalty)\n",
       "- **Value**: Provides fallback if TLS-BOOST fails, enables ADC + TLS-BOOST combination\n",
       "- **Timeline**: 2026-2027 after TLS-BOOST Phase II data informs need\n",
       "\n",
       "### **Priority #3: Diagnostic Partner for CDx-IFNG**\n",
       "- **Target**: Tempus, Foundation Medicine, Guardant\n",
       "- **Structure**: Integrate CDx-IFNG into their multi-gene panels as \"IFNŒ≥ Pathway Integrity Module\"\n",
       "- **Terms**: $10M development milestone, $50-100/test royalty, co-exclusive (you retain standalone Dx)\n",
       "- **Value**: Immediate commercialization path, leverages their CLIA labs and payer contracts\n",
       "- **Timeline**: 2025 after retrospective validation complete\n",
       "\n",
       "### **Priority #4: Oncogene-Targeted Therapy Partnership (IMM-201)**\n",
       "- **Target**: Janssen (amivantam"
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "display(Markdown(\"## üíº Demo 3: Multi-Asset Portfolio Optimization\"))\n",
    "\n",
    "query_3 = \"\"\"Optimize our IO portfolio strategy using conference intelligence:\n",
    "\n",
    "CURRENT PORTFOLIO:\n",
    "\n",
    "Asset 1:\n",
    "- Name: IMM-201 (anti-GM-CSF mAb)\n",
    "- MOA: GM-CSF neutralization\n",
    "- Stage: Phase 2 ready\n",
    "- Current indication: None selected\n",
    "\n",
    "Asset 2:\n",
    "- Name: TLS-BOOST (LIGHT agonist)\n",
    "- MOA: TNFSF14 agonist, induces tertiary lymphoid structures\n",
    "- Stage: Phase 1\n",
    "- Current indication: Solid tumors, not specified\n",
    "\n",
    "Asset 3:\n",
    "- Name: CDx-IFNG (diagnostic)\n",
    "- MOA: N/A (companion diagnostic for IFNG expression)\n",
    "- Stage: Analytical validation\n",
    "- Current indication: ICI patient selection\n",
    "\n",
    "PORTFOLIO QUESTIONS:\n",
    "1. Which conference targets should each asset pursue? (provide ranking)\n",
    "2. Are there synergistic combinations within our portfolio?\n",
    "3. Which assets compete vs complement each other?\n",
    "4. Optimal sequencing of trials to maximize learning and efficiency?\n",
    "5. Resource allocation recommendations (which to prioritize)?\n",
    "6. Partnership opportunities based on conference data gaps?\n",
    "7. 5-year portfolio roadmap with decision points\n",
    "\n",
    "Provide portfolio optimization matrix with success probabilities.\n",
    "\"\"\"\n",
    "\n",
    "print(\"üì§ Sending query to LLM...\")\n",
    "print(\"‚è±Ô∏è  This may take 30-40 seconds...\\n\")\n",
    "\n",
    "response_3 = query_llm(query_3, max_tokens=6000)\n",
    "\n",
    "print(\"‚úÖ Response received!\\n\")\n",
    "display(Markdown(response_3))"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
